Literature DB >> 2642853

Fate of late complications in type I diabetic patients after successful pancreas-kidney transplantation.

R Landgraf1, J Nusser, W Müller, M M Landgraf-Leurs, S Thurau, M Ulbig, A Kampik, B Lachenmayr, G Hillebrand, S Schleibner.   

Abstract

The success rate of pancreas transplantation allows us to study in more detail the potential beneficial effects of normoglycemia on secondary complications in diabetes mellitus. We report a prospective follow-up (mean 26 mo) of metabolic control, neuropathy, retinopathy, and peripheral microcirculation in 31 patients with type I (insulin-dependent) diabetes (mean age 33 +/- 1 yr; mean duration of diabetes 21 +/- 1 yr) after combined kidney and segmental pancreas grafting. All patients had normal HbA1 levels. Glucose tolerance (GT), insulin, C-peptide, and glucagon were normal in 22 patients, and impaired oral GT with reduced insulin secretory capacity was seen in 9 patients. During follow-up, there was no deterioration of GT and insulin release. Vascular risk factors, e.g., hypertension, cholesterol, and triglycerides, decreased after grafting. Autonomic neuropathy improved clinically, and R-R variation increased significantly in 3 of 18 patients. Peripheral neuropathy improved clinically in 46% of patients and did not deteriorate in the others. Motor nerve conduction velocity increased greater than 20% in 8, less than 20% in 12, and was unchanged in 8 of 28 recipients. Most of the patients (n = 30) had pretransplant laser treatment of their advanced retinopathy. Posttransplant visual acuity improved at least more than one line in 56%, stabilized in 32%, and deteriorated in 12% of patients. Patients with functioning grafts for greater than 1 yr had no further deterioration of visual acuity. Vitreous hemorrhage frequency and severity dropped markedly from pretransplant (from 69 to 24%) 10 mo after grafting. Retinal morphology remained stable in all eyes except two.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2642853     DOI: 10.2337/diab.38.1.s33

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  7 in total

1.  Determinants of a normal (versus impaired) oral glucose tolerance after combined pancreas-kidney transplantation in IDDM patients.

Authors:  F Pfeffer; M A Nauck; S Benz; A Gwodzinski; R Zink; M Büsing; H D Becker; U T Hopt
Journal:  Diabetologia       Date:  1996-04       Impact factor: 10.122

Review 2.  [Normoglycemia as a therapy goal in diabetes treatment--concept and realization].

Authors:  E G Siegel
Journal:  Klin Wochenschr       Date:  1990-03-16

3.  Basal and nutrient-stimulated pancreatic and gastrointestinal hormone concentrations in type-1-diabetic patients after successful combined pancreas and kidney transplantation.

Authors:  M A Nauck; M Büsing; C Orskov; E G Siegel; J Talartschik; A Baartz; T Baartz; H Hölzer; U T Hopt; R Ebert
Journal:  Clin Investig       Date:  1992-01

4.  Long-term metabolic control in recipients of combined pancreas and kidney transplants.

Authors:  H Holdaas; I B Brekke; A Hartmann; O H Bentdal; T Ganes; A Gjellestad; P Fauchald; K J Berg; O Djøseland; J Jervell
Journal:  Diabetologia       Date:  1991-08       Impact factor: 10.122

5.  Diabetic microangiopathy in type 1 (insulin-dependent) diabetic patients after successful pancreatic and kidney or solitary kidney transplantation.

Authors:  D Abendroth; J Schmand; R Landgraf; W D Illner; W Land
Journal:  Diabetologia       Date:  1991-08       Impact factor: 10.122

6.  Sequential electrodiagnostic evaluation of diabetic neuropathy after combined pancreatic and renal transplantation.

Authors:  C Vial; X Martin; N Lefrancois; J M Dubernard; F Chauvin; B Bady
Journal:  Diabetologia       Date:  1991-08       Impact factor: 10.122

7.  Long-term follow-up of diabetic retinopathy for up to 71 months after combined renal and pancreatic transplantation.

Authors:  M Ulbig; A Kampik; S Thurau; R Landgraf; W Land
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1991       Impact factor: 3.117

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.